<DOC>
	<DOCNO>NCT02748863</DOCNO>
	<brief_summary>The aim study demonstrate efficacy , safety tolerability 2 mL pre-filled syringe 300 mg secukinumab treatment moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Study Secukinumab With 2 mL Pre-filled Syringes</brief_title>
	<detailed_description>This 52-weeks multicenter , randomize , double-blind , placebo-controlled , parallel-group trial approximately 210 subject moderate severe plaque-type psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects eligible inclusion study must fulfill follow criterion : 1 . Subjects must able understand communicate investigator comply requirement study must give write , sign date informed consent study relate activity perform . Where relevant , legal representative also sign inform study consent accord local law regulation . 2 . Men woman least 18 year age time Screening . 3 . Chronic plaquetype psoriasis present least 6 month diagnose Randomization . 4 . Moderate severe psoriasis define Randomization : PASI score 12 great , IGA mod 2011 score 3 great ( base scale 0 4 ) , Body Surface Area ( BSA ) affect plaquetype psoriasis 10 % great . 5 . Candidate systemic therapy . This define subject moderate severe chronic plaquetype psoriasis inadequately control Topical treatment and/or Phototherapy and/or Previous systemic therapy 1 . Forms psoriasis chronic plaquetype ( e.g. , pustular , erythrodermic guttate psoriasis ) Screening Randomization . 2 . Ongoing use prohibit treatment . Washout period detail protocol adhere . Subjects willing limit UV light exposure ( e.g. , sunbathe and/or use tan device ) course study consider eligible study since UV light exposure prohibit . Note : administration live vaccine 6 week prior Randomization study period also prohibit . 3 . Previous exposure secukinumab ( AIN457 ) biologic drug directly target IL17 IL17 receptor . 4 . Use investigational drug time enrollment , within 5 halflives enrollment , within 30 day expect pharmacodynamic effect return baseline , whichever longer ; longer require local regulation . 5 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 6 . History lymphoproliferative disease know malignancy history malignancy organ system treat untreated within past 5 year , regardless whether evidence local recurrence metastasis ( except Bowen 's disease , basal cell carcinoma actinic keratoses treat evidence recurrence past 12 week ; carcinoma situ cervix noninvasive malignant colon polyp remove ) . 7 . History hypersensitivity study drug constituent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>secukinumab</keyword>
	<keyword>pre-filled syrinx</keyword>
</DOC>